中东和非洲血尿治疗市场预测至 2028 年 - COVID-19 影响和治疗(药物、疗法等)、适应症(尿路感染、肾结石、尿道炎、血癌、膀胱结石、前列腺癌、膀胱炎)的区域分析、创伤、剧烈运动、多囊肾病、子宫内膜异位症和月经)、类型(肉眼血尿、显微镜下血尿、特发性血尿和慢跑者血尿)、最终用户(医院、诊所和门诊手术中心等)

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 170    |    Report Code: TIPRE00026251    |    Category: Life Sciences

Middle East & Africa Hematuria Treatment Market

市场介绍

血尿是一种在尿液中发现血液的疾病。一般来说,尿液中不含红细胞,因此可能会导致严重的问题,还可能导致肾结石、尿路感染和其他遗传性疾病。

此外,血尿的患病率很高预计相关迹象将在预测期内促进市场增长。然而,相关适应症的未确诊病例限制了中东和非洲地区的增长。非洲血尿治疗市场。

在中东和非洲地区,重症监护病房 (ICU) 住院的患者人数不断增加,处方药物数量也在增加,导致许多诊断以及已经不堪重负的医疗保健系统的治疗问题。 COVID-19 症状主要见于肺部系统,但泌尿生殖系统的表现和/或后果要特别注意。老年 CKD 患者发生严重感染的风险较高,而 AKI 与高死亡率相关。因此,有必要监测重症COVID-19患者的肾功能,CRRT保护肾功能和消除危重患者的细胞因子对于改善康复至关重要。另一方面,COVID-19 感染似乎会对泌尿生殖道产生影响。治疗 COVID-19 时,应考虑泌尿生殖器官。

市场概况和动态

中东和中东地区非洲血尿治疗市场预计将从2021年的4200万美元增至2028年的4680万美元;预计 2021 年至 2028 年复合年增长率为 1.5%。慢性肾病 (CKD) 是一种常见且危及生命的疾病,影响更多人群。 CKD 有多种类型,如肾结石、肾小球肾炎、多囊肾和尿路感染。 CKD 是血尿流行的主要原因之一。此外,65岁以上女性的尿路感染患病率约为20%,而总人口的患病率约为11%。目前,中东和非洲非洲血尿治疗市场因相关适应症的日益流行而显着增长。

主要细分市场

从类型上看,肉眼血尿段在中东和中东地区所占比例最大。 2020年非洲血尿治疗市场。在治疗方面,药物细分市场占中东及非洲地区最大份额。 2020年非洲血尿治疗市场。从适应症来看,中东和非洲尿路感染细分市场占据最大份额。 2020年非洲血尿治疗市场。就最终用户而言,医院细分市场占据中东和非洲地区最大份额。 2020年非洲血尿治疗市场。

主要来源和上市公司

准备这份关于中东和中东地区血尿治疗市场的报告时提到了一些主要的一手和二手资料来源。非洲有公司网站、年度报告、财务报告、国家政府文件、统计数据库等。报告中列出的主要公司包括阿斯利康、百时美施贵宝公司、F. HOFFMANN-LA ROCHE LTD.、葛兰素史克公司、杨森制药、默沙东制药公司和默沙东制药公司。 Co., Inc.、Novartis AG、Pfizer Inc.、Sun Pharmaceutical Industries Ltd 和 Boehringer Ingelheim International GmbH。

购买原因报告

  • 了解中东和中东地区非洲血尿治疗市场格局并确定可能保证丰厚回报的细分市场
  • 了解不断变化的市场格局并在竞争中保持领先
  • 有效规划中东和非洲地区的并购和合作交易。通过识别最有希望销售的细分市场,非洲血尿治疗市场
  • 通过对各个细分市场的市场表现进行敏锐和全面的分析,做出明智的业务决策
  • 获取中东及中东地区市场收入预测2021年至2028年按不同细分市场划分的非洲血尿治疗市场

中东和非洲非洲血尿治疗市场细分

作者

治疗

  • 药物
  • 疗法
  • 其他

按指示

  • 尿路感染
  • 肾结石
  • 尿道炎
  • 血癌
  • 膀胱结石
  • 前列腺癌
  • 膀胱炎
  • 外伤
  • 剧烈运动
  • 多囊肾
  • 子宫内膜异位症
  • 月经
  • 子宫内膜异位症
  • 月经
  • span>

类型

  • 肉眼血尿
  • 显微镜下血尿
  • 特发性血尿
  • 慢跑者血尿

最终用户

  • 医院
  • 诊所
  • 门诊手术中心 (ASC)
  • 其他

按国家/地区

    < li>中东和中东非洲
    • 阿联酋
    • 沙特阿拉伯
    • 南非
    • 中东其他地区和地区非洲

提及的公司

< ul>
  • 阿斯利康
  • 百时美施贵宝公司
  • F. HOFFMANN-LA ROCHE LTD.
  • 葛兰素史克公司
  • 杨森制药
  • 默克公司有限公司
  • 诺华公司
  • 辉瑞公司
  • < span>太阳制药工业有限公司
  • 勃林格殷格翰国际有限公司


  • Middle East & Africa Hematuria Treatment Strategic Insights

    Strategic insights for Middle East & Africa Hematuria Treatment involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

    strategic-framework/middle-east-and-africa-hematuria-treatment-market-strategic-framework.webp
    Get more information on this report

    Middle East & Africa Hematuria Treatment Report Scope

    Report Attribute Details
    Market size in 2021 US$ 42.0 Million
    Market Size by 2028 US$ 46.8 Million
    Global CAGR (2021 - 2028) 1.5%
    Historical Data 2019-2020
    Forecast period 2022-2028
    Segments Covered By 治疗
    • 药物
    • 疗法
    By 适应症
    • 泌尿道感染
    • 肾结石
    • 尿道炎
    • 血癌
    • 膀胱结石
    • 前列腺癌
    • 膀胱炎
    • 创伤
    • 剧烈运动
    • 多囊肾病
    • 子宫内膜异位症
    • 月经
    By 类型
    • 肉眼血尿
    • 显微镜下血尿
    • 特发性血尿
    • 慢跑者血尿
    By 最终用户
    • 医院
    • 诊所
    • 门诊手术中心
    Regions and Countries Covered 中东和非洲
    • 南非
    • 沙特阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
    Market leaders and key company profiles
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Get more information on this report

    Middle East & Africa Hematuria Treatment Regional Insights

    The regional scope of Middle East & Africa Hematuria Treatment refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/middle-east-and-africa-hematuria-treatment-market-geography.webp
    Get more information on this report

    The List of Companies - Middle East & Africa Hematuria Treatment Market

    1. AstraZeneca
    2. Bristol-Myers Squibb Company
    3. F. HOFFMANN-LA ROCHE LTD.
    4. GlaxoSmithKline plc.
    5. Janssen Pharmaceuticals
    6. Merck & Co., Inc.
    7. Novartis AG
    8. Pfizer Inc.
    9. Sun Pharmaceutical Industries Ltd
    10. Boehringer Ingelheim International GmbH
    Frequently Asked Questions
    How big is the Middle East & Africa Hematuria Treatment Market?

    The Middle East & Africa Hematuria Treatment Market is valued at US$ 42.0 Million in 2021, it is projected to reach US$ 46.8 Million by 2028.

    What is the CAGR for Middle East & Africa Hematuria Treatment Market by (2021 - 2028)?

    As per our report Middle East & Africa Hematuria Treatment Market, the market size is valued at US$ 42.0 Million in 2021, projecting it to reach US$ 46.8 Million by 2028. This translates to a CAGR of approximately 1.5% during the forecast period.

    What segments are covered in this report?

    The Middle East & Africa Hematuria Treatment Market report typically cover these key segments-

  • 治疗 (药物, 疗法)
  • 适应症 (泌尿道感染, 肾结石, 尿道炎, 血癌, 膀胱结石, 前列腺癌, 膀胱炎, 创伤, 剧烈运动, 多囊肾病, 子宫内膜异位症, 月经)
  • 类型 (肉眼血尿, 显微镜下血尿, 特发性血尿, 慢跑者血尿)
  • What is the historic period, base year, and forecast period taken for Middle East & Africa Hematuria Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Hematuria Treatment Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Middle East & Africa Hematuria Treatment Market?

    The Middle East & Africa Hematuria Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Who should buy this report?

    The Middle East & Africa Hematuria Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Middle East & Africa Hematuria Treatment Market value chain can benefit from the information contained in a comprehensive market report.